Add-on Acquisition • Life Science

Idera Pharmaceuticals Acquires Aceragen

On September 28, 2022, Idera Pharmaceuticals acquired life science company Aceragen

Acquisition Context

This is Idera Pharmaceuticals’ 1st transaction in the Life Science sector.
This is Idera Pharmaceuticals’ 1st transaction in the United States.
This is Idera Pharmaceuticals’ 1st transaction in North Carolina.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	September 28, 2022
Target	Aceragen
Sector	Life Science
Buyer(s)	Idera Pharmaceuticals
Deal Type	Add-on Acquisition
Advisor(s)	Wedbush Securities (Financial) Fenwick & West (Legal)

Target Company

Aceragen

Research Triangle Park, North Carolina, United States

Aceragen is a biopharmaceutical company developing innovative therapeutics for rare and orphan diseases. The Company is advancing ACG-801 (rhAC) as an investigational enzyme replacement therapy for the treatment of patients with Farber disease and potentially other diseases associated with the dysregulation of ceramide metabolism, including cystic fibrosis. Its other development lead is ACG-721, an oral small molecule candidate for cystic fibrosis pulmonary exacerbations and related orphan infectious diseases. Aceragen is based in Research Triangle Park, North Carolina.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer